Wave Life Sciences Ltd [WVE] stock prices are down -2.73% to $17.48 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The WVE shares have gain 6.52% over the last week, with a monthly amount glided 147.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Wave Life Sciences Ltd [NASDAQ: WVE] stock has seen the most recent analyst activity on December 12, 2025, when Wedbush reiterated its Outperform rating and also boosted its price target to $33 from $20. Previously, RBC Capital Mkts upgraded its rating to Outperform on December 09, 2025, and kept the price target unchanged to $27. On October 20, 2025, Wells Fargo initiated with a Overweight rating and assigned a price target of $18 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $19 on August 04, 2025. Oppenheimer initiated its recommendation with a Outperform and recommended $24 as its price target on July 28, 2025. Citigroup started tracking with a Buy rating for this stock on July 16, 2025, and assigned it a price target of $16.
The stock price of Wave Life Sciences Ltd [WVE] has been fluctuating between $5.28 and $21.73 over the past year. Currently, Wall Street analysts expect the stock to reach $31.54 within the next 12 months. Wave Life Sciences Ltd [NASDAQ: WVE] shares were valued at $17.48 at the most recent close of the market. An investor can expect a potential return of 80.43% based on the average WVE price forecast.
Analyzing the WVE fundamentals
The Wave Life Sciences Ltd [NASDAQ:WVE] reported sales of 109.23M for trailing twelve months, representing a surge of 199.11%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.24%, Pretax Profit Margin comes in at -1.12%, and Net Profit Margin reading is -1.12%. To continue investigating profitability, this company’s Return on Assets is posted at -4.71, Equity is -0.73 and Total Capital is 2.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.96 points at the first support level, and at 16.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.11, and for the 2nd resistance point, it is at 18.74.
Ratios To Look Out For
It’s worth pointing out that Wave Life Sciences Ltd [NASDAQ:WVE]’s Current Ratio is 2.51. Also, the Quick Ratio is 2.51, while the Cash Ratio stands at 2.28. Considering the valuation of this stock, the price to sales ratio is 29.28, the price to book ratio is 22.50.
Transactions by insiders
Recent insider trading involved GSK plc, 10% Owner, that happened on Dec 11 ’25 when 1.47 million shares were purchased. Director, Rawcliffe Adrian completed a deal on Dec 08 ’25 to sell 42000.0 shares. Meanwhile, Director Wagner Heidi L sold 14000.0 shares on Dec 08 ’25.
